We recently demonstrated that leukocyte Ig-like receptor 4 (LILRB4) expressed by monocytic acute myeloid leukemia (AML) cells mediates T-cell inhibition and leukemia cell infiltration via its intracellular domain. The cytoplasmic domain of LILRB4 contains three immunoreceptor tyrosine-based inhibitory motifs (ITIMs); the tyrosines at positions 360, 412, and 442 are phosphorylation sites. Here, we analyzed how the ITIMs of LILRB4 in AML cells mediate its function. Our in vitro and in vivo data show that Y 412 and Y 442 , but not Y 360 , of LILRB4 are required for T-cell inhibition, and all three ITIMs are needed for leukemia cell infiltration. We constructed chimeric proteins containing the extracellular domain of LILRB4 and the intracellular domain of LILRB1 and vice versa. The intracellular domain of LILRB4, but not that of LILRB1, mediates T-cell suppression and AML cell migration. Our studies thus defined the unique signaling roles of LILRB4 ITIMs in AML cells.
INTRODUCTION
The leukocyte Ig-like receptor subfamily B (LILRB) proteins are a group of type I transmembrane glycoproteins with extracellular Iglike domains that bind ligands and intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that can recruit the tyrosine phosphatases SHP-1 and SHP-2, and/or the inositol phosphatase SHIP. [1] [2] [3] [4] [5] [6] LILRBs are expressed on various types of immune and non-immune cells. 1 Because of the negative roles of phosphatases in immune activation, LILRBs are considered to be immune checkpoint factors. 7 LILRBs are also expressed by tumor cells, notably hematopoietic cancer cells. 1, 8, 9 We have shown that several LILRBs and a related ITIM receptor, LAIR1, support AML development. [10] [11] [12] [13] Consistently, other laboratories have demonstrated that LILRB4, LILRB1, and LAIR1 support tumor development, [14] [15] [16] and several LILRBs have been suggested to be AML target candidates. 17 LILRB4 (also known as ILT3, LIR5, and CD85K) is expressed specifically on normal monocytic cells (monocytes, macrophages, and some dendritic cells) 13, 18 and to a lesser extent on plasmablasts 19 but not on hematopoietic progenitor or stem cells. 1, 12, 13, 20, 21 LILRB4 is a marker for monocytic AML, and it is expressed at significantly higher levels on monocytic AML cells than on normal hematopoietic cells. 12, 13, 21, 22 It is noteworthy that LILRB4 is primate-specific. The expression pattern and ligand of the mouse orthologue of LILRB4-gp49B1-are different from those of LILRB4. 1, 12 Therefore, the gp49B1 knockout mouse model may not be appropriate for use in experiments seeking to elucidate the biological significance of LILRB4.
We discovered that LILRB4 supports tumor growth by facilitating leukemia cell infiltration into tissues and by suppressing T-cell activity through the apolipoprotein E (ApoE)/LILRB4/tyrosineprotein phosphatase nonreceptor type 11 (SHP-2)/nuclear factor kappa-B (NFκB)/urokinase receptor (uPAR)/arginase-1 (ARG1) axis in AML cells. 12, 22 Extracellular ApoE can activate LILRB4 on monocytic AML cells, and the intracellular domain of LILRB4 is required to mediate the signaling and activities. 12 The activated LILRB4 subsequently recruits SHP-2 and upregulates NFκB. 12, 22, 23 Downstream effectors of NFκB in AML cells, including ARG1 and uPAR, lead to inhibition of T-cell proliferation and promotion of tissue infiltration. 12 In addition, we also developed anti-LILRB4 CAR-T cells that efficiently inhibited AML development in vitro and in vivo. 12, 13 LILRB4 thus represents an attractive target for treating monocytic AML. Our work suggests that LILRBs have dual roles in tumor biology: as immune checkpoint molecules and as tumorsustaining factors. 1 How the intracellular domain of LILRB4 regulates signaling is an unresolved question. ITIMs are thought to be the only signaling motif in LILRBs. LILRB4 contains three ITIMs, with tyrosines at positions 360, 412, and 442 as phosphorylation sites. 18, 24, 25 The functions of LILRB4 ITIMs in malignant cells remain unknown. To define the roles of the individual ITIMs of LILRB4 in mediating LILRB4 functions in cancer cells, we individually mutated each of these tyrosines to phenylalanines to disrupt ITIM domain functions, swapped the domains of LILRB1 and LILRB4, and used functional assays to analyze the effects.
RESULTS
Tyrosines at positions 412 and 442 but not 360 in ITIMs are required for the T-cell inhibition mediated by LILRB4 in leukemia cells The intracellular domain of LILRB4 contains three ITIMs centered on Y 360 (VTYAKV), Y 412 (VTYARL), and Y 442 (SVYATL). 18, 24, 25 To identify the tyrosine residues that mediate T-cell suppression and AML cell infiltration, we mutated each tyrosine to phenylalanine and introduced a version of LILRB4 with single, double, or triple mutations into lilrb4-KO THP-1 monocytic AML cells by lentivirusmediated transduction (Fig. 1a ). We cocultured wild-type control and engineered THP-1 cells with primary human T cells without cell-cell contact in a 96-well permeable support system. The dilution of CFSE represents T-cell proliferation (Supplementary Figs. S1A and B). Consistent with our previous observations, 12 the lilrb4-WT but not the lilrb4-KO THP-1 cells inhibited T-cell proliferation, and the KO phenotype was reversed by the expression of lilrb4 in lilrb4-KO THP-1 cells (lilrb4-Res cells) ( Fig. 1b , c, Supplementary Figs. S1C and D). Interestingly, in cocultures with lilrb4-KO cells in which the Y 360 F mutant was expressed, T-cell proliferation was inhibited to the same extent as was observed upon expression of WT LILRB4. In contrast, expression of Y 412 F or Y 442 F did not restore wild-type levels of inhibition of T-cell proliferation ( Fig. 1b , c, Supplementary Figs. S1 B, C and D). The expression of the double mutants or the triple mutant in lilrb4-KO cells did not restore T-cell inhibition ( Fig. 1b , c, Supplementary Figs. S1B, C and D). Similar results were obtained when LILRB4 constructs were expressed in MV4-11 lilrb4-KO cells ( Fig. 1d -e, Supplementary Fig. S2 ). These results indicate that Y 412 and Y 442 , but not Y 360 , are required for LILRB4-mediated T-cell inhibition by monocytic AML cells.
Next, we used a humanized mouse xenograft model to determine the function of ITIMs in immune checkpoint blockade in vivo. Immune compromised NOD-scid IL2Rγ-knockout (NSG) mice were humanized by injection of human PBMCs. THP-1 cells expressing lilrb4 constructs were subcutaneously transplanted into the humanized mice, and the tumor development and T-cell numbers were monitored. Tumors developed significantly faster in groups transplanted with lilrb4-WT, lilrb4-Res, and lilrb4-Y 360 F cells than in groups transplanted with lilrb4-KO, lilrb4-Y 412 F, and lilrb4-Y 442 F cells ( Fig. 2a-c) . Moreover, human CD3 + T-cell percentages in peripheral blood were significantly higher in the lilrb4-KO, lilrb4-Y 412 F, and lilrb4-Y 442 F groups than in the lilrb4-WT, lilrb4-Res, and lilrb4-Y 360 F groups ( Fig. 2d ). Thus, in vitro and in vivo data indicate that T-cell inhibition is mediated by the two distal ITIMs (Y 412 and Y 442 ) but not the proximal ITIM (Y 360 ) of LILRB4 in AML cells.
All three ITIMs of LILRB4 influence leukemia cell infiltration Patients with monocytic AML are more likely to have extramedullary infiltration than patients with other leukemias, 26, 27 and LILRB4-mediated signaling supports the infiltration activity of monocytic AML cells. 12 To determine which ITIMs mediate this tissue infiltration ability, we employed a trans-endothelial migration assay to compare the abilities of LILRB4 ITIM mutants to migrate through endothelial cells. A much higher number of THP-1 cells that expressed lilrb4-WT migrated through the endothelial cells than did THP-1 cells that expressed lilrb4-KO; expression of lilrb4 in the lilrb4-KO cells (lilrb4-Res) rescued the defective migration of lilrb4-KO cells ( Fig. 3a, b ), consistent with our previous report. 12 Interestingly, the cells with single, double, or triple mutations of the tyrosines in the ITIM domains all demonstrated less trans-endothelial migration than was observed for cells that expressed wild-type LILRB4 ( Fig. 3a, b , Supplementary  Fig. S3 ).
To validate the in vitro results, we analyzed the short-term infiltration abilities of lilrb4-KO MV4-11 cells that stably expressed various LILRB4 mutants in vivo. The ratio of GFP + cells to peripheral blood represented the infiltration abilities, and the GFP + cell percentages in peripheral blood, bone marrow, spleen and liver are shown in Supplementary Figs. S4 and S5. The lilrb4-KO cells injected intravenously into NSG mice had significantly less infiltration into the bone marrow, spleen, and liver than lilrb4-WT cells. Expression of lilrb4 in the lilrb4-KO cells significantly promoted the infiltration of the cells into these organs ( Fig. 3c-e ). In contrast, leukemia cell infiltration into the bone marrow, spleen, and liver was significantly reduced when any of the ITIMs were mutated ( Fig. 3c-e ). Therefore, we conclude that each ITIM of LILRB4 regulates the AML cell infiltration capacity.
Y412 and Y442, but not Y360, recruit SHP-2 to activate downstream signaling The intracellular domain of activated LILRB4 recruits SHP-2, which activates NFκB. 12 NFκB regulates downstream effectors, including uPAR 28 and ARG1, 29 to inhibit T-cell proliferation and promote the infiltration of AML cells into tissues. 12, 22 To identify the ITIMs responsible for SHP-2 recruitment, we first used immunohistochemistry to evaluate the levels of the signaling molecules downstream of LILRB4 in tumor sections from humanized NSG mice transplanted with lilrb4-KO THP-1 cells expressing the LILRB4 constructs. The staining of phospho-SHP-2 (Y 580 ), phospho-P65 (S 536 ), and ARG1 was significantly more intense in samples from the lilrb4-WT, lilrb4-Res, and lilrb4-Y 360 F groups than in samples from the lilrb4-KO and lilrb4-Y 412 F groups (Fig. 4 ). The analysis was not performed for the lilrb4-Y 442 F group because no tumors formed in these mice.
Coimmunoprecipitation (co-IP) was conducted to validate the recruitment. SHP-2 was recruited to LILRB4 in lilrb4-WT but not KO cells, and forced expression of lilrb4 in the lilrb4-KO cells led to rerecruitment of SHP-2 ( Supplementary Fig. S6A ). SHP-2 could be recruited to Y 360 F, Y 412 F, Y 442 F, Y 360-412 F, and Y 360-442 F mutants, but not to Y 412-442 F or Y 360-412-442 F mutants ( Supplementary Fig.  S6A ), suggesting that Y 412 and Y 442 of LILRB4 contribute to SHP-2 recruitment.
Western blotting and flow cytometry were used to detect downstream molecules, including phospho-SHP-2, phospho-P65, ARG1, and uPAR, in stably engineered THP-1 cells. The results showed that the levels of phosphorylation of SHP-2 on the Y 580 residue, P65 on the S 536 residue, ARG1 and uPAR were decreased upon lilrb4 knockout, and their levels could be rescued when wildtype lilrb4 was expressed in the lilrb4-KO cells ( Fig. 5a-d ). The levels of phospho-SHP-2 (Y 580 ), phospho-P65 (S 536 ), ARG1, and uPAR were similar in lilrb4-Y 360 F cells and lilrb4-WT cells; however, their levels were decreased in lilrb4-Y 412 F and lilrb4-Y 442 F cells ( Fig. 5 ). These results suggest that Y 412 and Y 442 , but not Y 360 , are involved in the downstream signaling mediated by LILRB4 in AML cells.
Furthermore, we found that all three ITIMs of LILRB4 were involved in the regulation of the extramedullary infiltration of AML cells (Fig. 3 ). The F-actin level was significantly decreased in lilrb4-KO cells compared with that in the lilrb4-WT group and was significantly restored in lilrb4-KO cells ectopically expressing lilrb4 ( Supplementary Fig. S6B ). F-actin was significantly reduced in the Y 360 F, Y 412 F, and Y 442 F mutants ( Supplementary Fig. S6B ), indicating that F-actin is regulated by the LILRB4 signaling that promotes the infiltration of AML cells.
The intracellular domain of LILRB4, but not that of LILRB1, mediates the T-cell suppression and infiltration of AML cells
The LILRB family contains five members with highly conservative ITIMs in their intracellular domains. 1 Whether the intracellular domains of other LILRBs can mediate the same signaling and function of LILRB4 is unknown. We engineered vectors for the expression of chimeric proteins with the extracellular domain (ECD) of LILRB4 or LILRB1 and the intracellular domain (ID) of the other and stably expressed these proteins in lilrb4-KO and lilrb1-KO cells (Fig. 6a, b ). LILRB1 was chosen for domain swapping for the following reasons. First, LILRB1 and LILRB4 have similar a Single, double, and triple mutants of phosphorylation sites (shown schematically above the FACS traces confirming expression) were constructed and expressed in THP-1 cells and MV4-11 cells in which lilrb4 was knocked out. In the construct schematics, wild-type ITIMs are indicated by red. b-e CD3 + T cells from a healthy donor labeled with CFSE were placed into the lower chamber with anti-CD3/CD28-coated beads and rhIL-2, and irradiated AML cells were placed into the upper chamber. The AML cells were (b, c) THP-1 cells expressing the indicated constructs and (d, e) MV4-11 cells expressing the indicated constructs. b, d Cells were photographed after 5 days (scale bar: 100 μm). c, e Cells were analyzed by flow cytometry. The dilution of CFSE corresponds to T-cell proliferation. Representative data from three independent experiments are presented (n = 3, means ± s.e.m.). *p < 0.05, **p < 0.01 expression patterns in monocytic AML cells. 1, 12 Second, LILRB1, LILRB2, and LILRB3 share certain identical AA sequences in their ITIMs. 1 Therefore, we used LILRB1 as a representative LILRB to compare with LILRB4.
lilrb4-WT but not lilrb4-KO AML cells were capable of significantly inhibiting T-cell proliferation; knockout of lilrb1 did not alter the T-cell inhibition ability of AML cells ( Fig. 6c, d , Supplementary Figs. S7 and S8). Interestingly, forced expression of the protein with the ECD of LILRB4 and the ID of LILRB1 did not rescue T-cell suppression, whereas T-cell proliferation was significantly inhibited in lilrb1-KO cells when the protein with the ECD of LILRB1 and the ID of LILRB4 was expressed ( Fig. 6c, d , Supplementary Figs. S7 and S8). The same result was obtained with a histidine-tagged (as the sorting marker for infected cells) version of this protein ( Fig. 6a, b , Supplementary Figs. S7 and S8). These results suggest that the ID of LILRB4 has a unique ability to inhibit T-cell proliferation.
LILRB4 supports the infiltration of AML cells into tissues and organs. 12 Whereas lilrb4-KO cells expressing the histidine-tagged protein with the ECD of LILRB1 and the ID of LILRB4 significantly enhanced the infiltration of lilrb4-KO cells, the expression of the chimera with the ID of LILRB1 did not promote trans-endothelial migration (Fig. 7a) . Expression of the protein with the ECD of LILRB1 and the ID of LILRB4 in lilrb1-KO cells did not significantly promote the trans-endothelial migration ability of THP-1 cells (Fig. 7a ). There is more robust endogenous LILRB4 signaling in THP-1 cells than signaling from other LILRBs (Fig. 1a) , which may make the effects of ectopic expression undetectable in THP-1 cells.
Next, we analyzed the expression of downstream signaling molecules of LILRB4. Compared with that in lilrb4-WT cells, the phospho-SHP-2 (Y 580 ) level was decreased in lilrb4-KO but not lilrb1-KO cells, consistent with a previous report that LILRB1 recruits SHP-1 but not SHP-2. 30 The phospho-SHP-2 (Y 580 ) level was increased in lilrb4-KO cells when the chimeric protein with the LILRB4 intracellular domain (His-Tag-B1-ECD-B4-ID) was ectopically expressed, whereas expression of the chimeric protein with the LILRB1 intracellular domain did not increase phospho-SHP-2 (Y 580 ) levels ( Fig. 7b and Supplementary Fig. S9A ). The phospho-P65 (S 536 ), ARG1, and uPAR levels were also increased by the expression of only the protein with the LILRB4 intracellular domain (Fig. 7b, c and Supplementary Figs. S9B-D) . Similar results were observed for F-actin ( Fig. 7d and Supplementary Fig. S9E ). Together, these results show that the intracellular domain of LILRB4 has a unique function in T-cell inhibition and infiltration by AML cells.
DISCUSSION
We previously demonstrated that LILRB4 supports tumor cell infiltration into tissues and suppresses T-cell activity via the ApoE/ LILRB4/SHP-2/uPAR/arginase-1 signaling axis in AML cells. 12 In this study, we focused on two questions: what ITIMs of LILRB4 are required for inhibiting T-cell proliferation and promoting infiltration of monocytic AML cells, and do the intracellular domains of another LILRB family member have similar signaling functions to those of LILRB4 in leukemia cells.
We found that the second (Y 412 ) and the third (Y 442 ) ITIMs of LILRB4, but not the first (Y 360 ), are required for LILRB4-mediated signaling and for the inhibition of T-cell proliferation induced by monocytic AML cells (Fig. 8) . Therefore, the two functions of LILRB4 in monocytic AML cells, T-cell inhibition and infiltration, depend on slightly different ITIMs and perhaps on different signaling effectors. The fact that the ITIMs in LILRB4 have different functions is in accordance with a recent report on the roles of LILRB4 ITIMs in monocyte functions, including TNFα production and bactericidal activity. 25 Both studies support the conclusion that the effects of LILRB4 ITIMs are related to context-and function-dependent differences in downstream signaling.
We also investigated whether the intracellular domain of LILRB1 has a similar function to that of LILRB4 in AML cells. Although both contain ITIMs, the intracellular domain of LILRB1 does not support the two functions of LILRB4 in AML cells. There are several possible reasons for this very unusual observation. First, it is possible that different signaling molecules (in addition to SHP-1 and SHP-2) can be recruited by different LILRB family members. LILRB1 contains four ITIMs. 30 Y 533 (NLYAAV) is needed for tyrosine phosphorylation and subsequent SHP-1 recruitment, whereas Y 644 (SIYATL) and Y 614 (VTYAQL) act as the SHP-1 docking sites. 30 Y 562 (VTYAEV) does not have an SHP-1-related signaling function. 30 It has been suggested that Y 562 is the main docking site for the Src kinase CSK and that Y 533 and Y 614 contribute to CSK binding; however, SHP-1 and CSK do not exist in the same LILRB1 complex. 30 PirB, a mouse orthologue of the LILRB family proteins, can interact with SHP-1, SHP-2, Btk, Src, Syk, and Yes, and PirB may recruit Hck to regulate noninhibitory signaling pathways. 29, 31 Based on these observations, it is possible that unique signaling molecules interact with each LILRB. Second, the net outcome of LILRB signaling can be regulated by other signaling pathways. For example, PirB signaling can be enhanced by TLR9 signaling activation, 5 and after LTB4-induced activation, PirB can interact with kinases such as JAK1, JAK2, Shc, and Crk. 27, 31 It is therefore possible that LILRB1 and LILRB4 respond differently to other pathways in AML cells. Third, although ITIMs are the only identified signaling motifs in LILRBs, additional motifs in LILRB1 or LILRB4 may work cooperatively with ITIMs. For example, the unique proline-rich motif of LILRB4 has the potential to interact with SH3-domain molecules. 32 It has been shown that LILRB4 levels on dendritic cells are upregulated by Tregs. 33, 34 It will be important to know whether membrane-bound protein-protein interactions or soluble factor(s) mediate this effect. Although it has been reported that the interaction of LILRB4 with CD166 mediates its inhibitory effect on tumor cells, 35 and we demonstrated that ApoE can activate LILRB4, further investigations are needed to clarify whether LILRB4 on monocytic cells (including dendritic cells) can directly bind and act on a surface protein (ideally an immune inhibitory receptor) on activated or regulatory T cells. In summary, we have defined the signaling roles of the ITIMs of LILRB4 in the inhibition of T-cell activity and the migration of AML cells. Our elucidation of the functions of the three ITIMs of LILRB4 in monocytic AML cells deepens our understanding of the mechanism by which this receptor regulates immune checkpoints and tumor development. These findings may also facilitate the engineering of ITIMs for the development of novel cell therapies.
MATERIALS AND METHODS

Cells
Human cell lines were purchased from ATCC. THP-1 and MV4-11 cells were cultured in RPMI-1640 medium (Sigma-Aldrich, R8758) with 10% heat-inactivated fetal bovine serum (FBS, Sigma-Aldrich, F2442) and 1% penicillin and streptomycin (P4333, Sigma-Aldrich). Human umbilical vascular endothelial cells (hUVECs) were cultured in an endothelial culture medium kit (EGM-BulletKit, Lonza). 293T cells were cultured in Dulbecco's modified Eagle's medium/ high glucose (Sigma-Aldrich, D5796) with 10% heat-inactivated fetal bovine serum and 1% penicillin and streptomycin. All cells were incubated at 37°C in a 5% CO 2 incubator.
Mice
Immune compromised NOD-scid IL2Rγ-knockout (NSG) mice were purchased from the animal core facility of the University of Texas Southwestern Medical Center (UTSW). All animal experiments were performed with the approval of the UT Southwestern Institutional Animal Care and Use Committee.
lilrb4-and lilrb1-knockout lines lilrb4 and lilrb1 were knocked out using the CRISPR-Cas9 system as described previously. 12 The sgRNA sequences were designed at http://crispr.mit.edu, and the sequences were as follows:
control sgRNA: 5′-GAACGACTAGTTAGGCGTGTA-3′ sgRNAs targeting lilrb4: sgRNA1: 5′-TGTTACTATCGCAGCCCTGT-3′; sgRNA2: 5′-GTAGGTCCCCCCGTGCACTG-3′; sgRNA3: 5′-CCTGTGACCTCAGTGCACGG-3′ sgRNAs targeting lilrb1: sgRNA1: 5′-TACTATGGTAGCGACACTGC-3′ sgRNA2: 5′-TCCCTCCTGAGTTCACCACG-3′ These sequences were subcloned into a sgRNA expression plasmid followed by introduction into cells by lentiviral His-Tag-B1-ECD-B4-ID. F: 5′-TCACCATCATGGAGGCTCTGGGGCAC CTCCCCAAGCCC-3′ R: 5′-AGAGGGGCGGGATCGCGGCCGCTTTAGTGGATGGCCAGAGT GGCATAG-3′ PCR fragments were amplified and cloned into the pLVX-IRES-ZsGreen vector using the InFusion kit (Takara Bio). Three single mutants (Y 360 F, Y 412 F, and Y 442 F), three double mutants (Y 360-412 F, Y 360-442 F, and Y 412-442 F), and one triple mutant (Y 360-412-442 F) were constructed using the following primers. The italics indicate the sites of mutations. Because the Y442 site is close to the C terminus of LILRB4, the tyrosine codon (TAT) was mutated to The desired fusions and mutations were confirmed by sequencing.
Lentivirus packaging and infection
The desired CRISPR-Cas9-based sgRNA vector or pLVX-IRES-ZsGreen-hlilrb4, pLVX-IRES-ZsGreen-B1-ECD-B4-ID, pLVX-IRES-ZsGreen-B4-ECD-B1-ID, pLVX-IRES-ZsGreen-His-Tag-B1-ECD-B4-ID, pLVX-IRES-ZsGreen-Y 360 F, pLVX-IRES-ZsGreen-Y 412 F, pLVX-IRES-ZsGreen-Y 442 F, pLVX-IRES-ZsGreen-Y 360-412 F, pLVX-IRES-ZsGreen-Y 360-442 F, pLVX-IRES-ZsGreen-Y 412-442 F, or pLVX-IRES-ZsGreen-Y 360-412-442 F vectors were mixed with psPAX2 and pMD2.G at a ratio of 4:3:1 and transfected into 293T cells using PolyJet Reagent (Signagen). After 48 and 72 h, virus-containing supernatants were collected for infection as previously described. 12 Leukemia cell and T-cell coculture assay As described previously, 12 we used the permeable support system (pore size 3.0 μm, Fisher Clontech) for the leukemia cell and T-cell coculture in U-bottom 96-well plates. We placed 5 × 10 4 human CD3 + T cells (all cells) isolated from the healthy donor peripheral blood into the lower chamber and irradiated THP-1 or MV4-11 cells (2.5 × 10 4 per well, 28 Gy) into the transwell upper chamber. T cells were labeled with CFSE (CellTrace CFSE Cell Proliferation Kit, Thermo Fisher Scientific). IL-2 (50 U/ml, Novoprotein) and Dynabeads Human T-activator CD3/CD28 (Thermo Fisher Scientific, (BioLegend, 362603, 1:100) , and anti-human uPAR-APC (BioLegend, VIM5, 1:100), were used. Samples from NSG mice were analyzed as described previously. 12 Trans-endothelial migration assays hUVECs were cultured at 3 × 10 5 cells per chamber in 24-well transwell upper chambers (8.0 μm, Fisher). After 3 days, 1 × 10 5 THP-1 or MV4-11 cells were added to the upper chamber. After 20 h, the medium was collected from the lower chamber, and GFP + cells were counted by flow cytometry to observe transendothelial migration. 12 Short-term infiltration assay For analysis of infiltration in vivo, 3 × 10 6 MV4-11 cells were intravenously transplanted into 6-8-week-old NSG mice by tail veil injection. After 20 h, peripheral blood was taken under anesthesia, and the mice were sacrificed. The spleen, liver, and bone marrow were collected, dissected by scissors, and filtered through 300 µm mesh filters to make single-cell suspensions. The number of GFP + cells was determined by flow cytometry with normalization to the cell numbers in peripheral blood.
Xenograft model in humanized mice As described previously, 12 fresh human peripheral blood mononuclear cells (PBMCs) were isolated from the buffy coat (Interstate Blood Bank, Memphis, TN) by Ficoll Hypaque density gradient separation (GE Lifesciences), and the red blood cells were removed by lysis. Each NSG mouse was given 1 × 10 7 human PBMCs by intraperitoneal injection. After 7 days, human CD3 + T cells were detected in peripheral blood by flow cytometry. Mice (10 mice/each group) were grouped according to the CD3 + T-cell levels, and 1 × 10 7 THP-1 lilrb4-wild-type (WT), lilrb4-knockout (KO), lilrb4-rescue (Res), lilrb4-Y 360 F, lilrb4-Y 412 F, or lilrb4-Y 442 F cells were subcutaneously implanted. The tumor sizes were measured every 5 days, and the T-cell percentage in peripheral blood was detected every 7 days. The mice were sacrificed under anesthesia when moribund. The tumor, spleen, bone marrow, and liver were isolated, and the human CD3 + T-cell percentage was detected by flow cytometry.
Western blotting
As described previously, 12 equal amounts of protein were separated by SDS-PAGE and then transferred to a nitrocellulose membrane. The primary antibodies used were anti-phospho-SHP-2 (Tyr 580 , Cell Signaling Technology, 13328S, 1:500), antiphospho-p65 (Ser 536 , Cell Signaling Technology, 3033T, 1:1000), anti-arginase-1 (Cell Signaling Technology, 9819, 1:1000), anti-Factin (Bioss, bs-1571R, 1:500), and anti-GAPDH (Cell Signaling Technology, 5174, 1:1000). Membranes were incubated with antibody overnight at 4°C.
Coimmunoprecipitation
Cells were collected and lysed by IP lysis buffer (0.025 M Tris, 0.15 M NaCl, 0.001 M EDTA, 1% NP-40, and 5% glycerol; pH = 7.4) with a protease inhibitor cocktail (Roche Diagnostics). The samples were incubated with anti-LILRB4 antibody overnight at 4°C. The magnetic beads (Invitrogen, 10003D) were added and incubated for 15 min at room temperature. The magnetic bead-Ab-Ag complex was washed 5 times, and the samples were separated by SDS-PAGE. Anti-SHP-2 (Cell Signaling Technology, 3397, 1:500) was incubated with the samples overnight at 4°C.
Immunohistochemistry
Paraffin-embedded tumor samples were treated as detailed in our previous reports. 12 Antibodies against phospho-SHP-2 (Y 580 , Cell Signaling Technology, 13328S, 1:200), phospho-P65 (S 536 , Cell Signaling Technology, 3033T, 1:200), and arginase-1 (Cell Signaling Technology, 9819, 1:200) were used for staining. Samples were scanned using a Hamamatsu NanoZoomer 2.0-HT (Meyer Instruments).
Statistical analysis
Representative data from three independent experiments or the indicated number of independent samples are presented, and statistical significance for two-sample comparisons was calculated by ANOVA. p < 0.05 was considered statistically significant.
